Valion Bio, Inc. Form 8-K Summary
Reporting context: This Current Report on Form 8-K was signed and filed on September 23, 2026, with the earliest reported event dated September 17, 2026. The filing concerns board changes, committee appointments, and the appointment of an interim chief executive officer. Valion Bio is incorporated in Delaware, trades on Nasdaq under “VBIO,” and identifies as an emerging growth company.
Leadership and Governance Changes
- Dean Zikria was appointed Interim Chief Executive Officer effective September 22, 2026. He remains a member of the Board.
- Sheryle Bolton resigned from the Board effective September 17, 2026. The filing states that her resignation did not result from any disagreement with the Company regarding operations, policies, or practices.
- Thomas Jensen was appointed Chair of the Board and Chair of the Compensation Committee effective September 17, 2026.
- Jared Malbin was appointed Chair of the Audit and Risk Committee effective September 17, 2026.
- Mr. Zikria was removed as an independent member of the Audit and Risk Committee, Compensation Committee, and Nominations and Corporate Governance Committee while serving as Interim CEO.
Interim CEO Consulting Agreement
- Mr. Zikria will receive a monthly consulting fee of $23,333.
- He will receive 50,000 restricted stock units under the Company’s Amended and Restated 2021 Equity Incentive Plan.
- He may receive an additional 50,000 RSUs if stockholders approve an increase to the equity plan, subject to Special Committee approval.
- He may be eligible for a cash bonus determined by the Board or Compensation Committee upon the closing of a strategic transaction, including a reverse merger, merger, or acquisition.
- Mr. Zikria is engaged as an independent contractor rather than an employee, agent, partner, or joint venturer.
- The agreement terminates on January 22, 2027, unless mutually extended for up to 12 months from its effective date.
Financial Metrics and Other Material Changes
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, operating performance, or financial guidance information. It also does not disclose a clear quantitative impact of the leadership changes on the Company’s financial condition.
Outlook, Risks, and Unusual Items
- The potential transaction-related cash bonus and additional RSU grant create contingent compensation obligations tied to a strategic transaction and stockholder approval.
- The leadership transition and committee reassignments may affect governance and strategic direction, but the filing provides no specific operational outlook or forecast.
- A press release dated September 23, 2026, was furnished as Exhibit 99.1 under Regulation FD. The filing states that this information is furnished, not filed, and is generally not subject to Section 18 liability or incorporated by reference into other filings unless expressly specified.
Key Facts for Investors to Verify
- Review the full consulting agreement filed as Exhibit 10.1, including vesting, termination, and transaction-bonus terms.
- Confirm the effective dates of the Board resignation, committee appointments, and Interim CEO appointment, noting that the filing references September 17, September 22, and September 23, 2026.
- Assess whether the proposed additional 50,000 RSUs require and receive stockholder approval to increase the equity plan.
- Monitor any strategic transaction, related contingent compensation, or subsequent permanent CEO appointment.
- Review the furnished Exhibit 99.1 press release for additional management commentary not included in the filing text.